COLORADO SPRINGS, Colo., May 27, 2014 (GLOBE NEWSWIRE) -- The Spectranetics Corporation (Nasdaq:SPNC), a developer and manufacturer of single-use medical devices used in minimally invasive procedures within the cardiovascular system, today announced that it intends to offer, subject to market conditions and other factors, $200 million aggregate principal amount of its convertible senior notes due 2034 (the "notes") in an underwritten public offering. Spectranetics also expects to grant the underwriter of the notes a 30-day option to purchase up to an additional $30 million aggregate principal amount of the notes.
Help employers find you! Check out all the jobs and post your resume.
